R J Farrell

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi Virtual colonoscopy: a gastroenterologist's perspective
    R J Farrell
    Department of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass, USA
    Dig Dis 17:185-93. 1999
  2. ncbi Ulcerative colitis
    Richard J Farrell
    Division of Gastroenterology, Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Lancet 359:331-40. 2002
  3. ncbi Celiac sprue
    Richard J Farrell
    Gastroenterology Division, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
    N Engl J Med 346:180-8. 2002
  4. ncbi High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy
    R J Farrell
    Sir Patrick Dun s Research Laboratory, Trinity College Dublin, St James s Hospital, Ireland
    Gastroenterology 118:279-88. 2000
  5. ncbi Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low
    R J Farrell
    Department of Clinical Medicine and Gastroenterology, St James s Hospital, Trinity College Dublin, Republic of Ireland
    Gut 47:514-9. 2000
  6. ncbi P-glycoprotein-170 inhibition significantly reduces cortisol and ciclosporin efflux from human intestinal epithelial cells and T lymphocytes
    R J Farrell
    Department of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Aliment Pharmacol Ther 16:1021-31. 2002
  7. ncbi Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial
    Richard J Farrell
    Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Gastroenterology 124:917-24. 2003
  8. ncbi Microbial factors in inflammatory bowel disease
    Richard J Farrell
    Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Dana 501, 330 Brookline Avenue, Boston, MA 02115, USA
    Gastroenterol Clin North Am 31:41-62. 2002
  9. ncbi Glucocorticoid resistance in inflammatory bowel disease
    R J Farrell
    Department of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    J Endocrinol 178:339-46. 2003
  10. ncbi Utility of intravenously administered contrast material at CT colonography
    M M Morrin
    Departments of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Ave, Boston MA 02215, USA
    Radiology 217:765-71. 2000

Collaborators

Detail Information

Publications39

  1. ncbi Virtual colonoscopy: a gastroenterologist's perspective
    R J Farrell
    Department of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass, USA
    Dig Dis 17:185-93. 1999
    ..This article describes the technical considerations, current clinical status, limitations, and potential indications of this new and exciting technology which gastroenterologists should not fear but embrace...
  2. ncbi Ulcerative colitis
    Richard J Farrell
    Division of Gastroenterology, Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Lancet 359:331-40. 2002
    ..By contrast with Crohn's disease, there are few clinical data on biological agents. Probiotics seem the most promising of several experimental and traditional agents that have been investigated in controlled clinical trials...
  3. ncbi Celiac sprue
    Richard J Farrell
    Gastroenterology Division, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
    N Engl J Med 346:180-8. 2002
  4. ncbi High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy
    R J Farrell
    Sir Patrick Dun s Research Laboratory, Trinity College Dublin, St James s Hospital, Ireland
    Gastroenterology 118:279-88. 2000
    ..Inflammatory bowel disease (IBD) poorly responsive to medical therapy may relate to MDR expression because glucocorticoids are known Pgp-170 substrates...
  5. ncbi Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low
    R J Farrell
    Department of Clinical Medicine and Gastroenterology, St James s Hospital, Trinity College Dublin, Republic of Ireland
    Gut 47:514-9. 2000
    ..There is concern that the incidence of non-Hodgkin's lymphoma (NHL) will rise with increasing use of immunosuppressive therapy...
  6. ncbi P-glycoprotein-170 inhibition significantly reduces cortisol and ciclosporin efflux from human intestinal epithelial cells and T lymphocytes
    R J Farrell
    Department of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Aliment Pharmacol Ther 16:1021-31. 2002
    ..To assess the role of P-glycoprotein-170 (P-gp) in transporting cortisol and ciclosporin from human intestinal epithelium and T lymphocytes...
  7. ncbi Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial
    Richard J Farrell
    Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Gastroenterology 124:917-24. 2003
    ..We assessed the relationship between antibodies to infliximab (ATI) and the loss of response postinfliximab, infusion reactions and, in a randomized trial, investigated whether intravenous hydrocortisone premedication can reduce ATI...
  8. ncbi Microbial factors in inflammatory bowel disease
    Richard J Farrell
    Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Dana 501, 330 Brookline Avenue, Boston, MA 02115, USA
    Gastroenterol Clin North Am 31:41-62. 2002
    ....
  9. ncbi Glucocorticoid resistance in inflammatory bowel disease
    R J Farrell
    Department of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    J Endocrinol 178:339-46. 2003
    ..In addition, the impact of disease heterogeneity on glucocorticoid responsiveness and recent advances in IBD pharmacogenetics are discussed...
  10. ncbi Utility of intravenously administered contrast material at CT colonography
    M M Morrin
    Departments of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Ave, Boston MA 02215, USA
    Radiology 217:765-71. 2000
    ....
  11. ncbi Diagnosis of celiac sprue
    R J Farrell
    Gastroenterology Division, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Am J Gastroenterol 96:3237-46. 2001
    ..We review the wide spectrum of celiac sprue, its variable clinical manifestations, and the current approach to diagnosis...
  12. ncbi Gastroenterological causes of pelvic pain
    S Banerjee
    Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    World J Urol 19:166-72. 2001
    ..This article discusses the major gastroenterological causes of pelvic pain...
  13. ncbi Potential impact of magnetic resonance cholangiopancreatography on endoscopic retrograde cholangiopancreatography workload and complication rate in patients referred because of abdominal pain
    R J Farrell
    Dept of Clinical Medicine, St James Hospital, Trinity College, Dublin, Ireland
    Endoscopy 33:668-75. 2001
    ..The aim was to assess the potential impact of MRCP on overall ERCP workload and patient outcome if MRCP were the primary investigation in patients referred for ERCP because of abdominal pain...
  14. ncbi MR cholangiopancreatography of pancreaticobiliary diseases: comparison of single-shot RARE and multislice HASTE sequences
    M M Morrin
    Department of Radiology, Mater Misericordiae Hospital, Dublin
    Clin Radiol 55:866-73. 2000
    ....
  15. ncbi Colorectal neoplasms: role of intravenous contrast-enhanced CT colonography
    Jacob Sosna
    Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Ave, Boston, MA 02215, USA
    Radiology 228:152-6. 2003
    ..To evaluate whether computed tomographic (CT) colonography with intravenously administered contrast material can help predict malignant differentiation of colorectal neoplasms (> or =10 mm in diameter)...
  16. ncbi Endoscopy in inflammatory bowel disease: indications, surveillance, and use in clinical practice
    David S Fefferman
    Center for Inflammatory Bowel Disease, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Dana 501, 330 Brookline Avenue, Boston, Massachusetts 02215, USA
    Clin Gastroenterol Hepatol 3:11-24. 2005
    ..Furthermore, endoscopy plays a key role in the surveillance of patients with long-standing colitis who are at increased risk for dysplasia and the development of colorectal cancer...
  17. ncbi Immunogenicity of biological agents in inflammatory bowel disease
    David S Fefferman
    Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Inflamm Bowel Dis 11:497-503. 2005
  18. ncbi CT colonography: colonic distention improved by dual positioning but not intravenous glucagon
    Martina M Morrin
    Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
    Eur Radiol 12:525-30. 2002
    ..While our results suggest that other smooth muscle relaxants, including butyl scopolamine, may only have a limited role in improving colonic distention in CT colonography, further studies are required...
  19. ncbi Safety of infliximab in Crohn's disease: a large single-center experience
    H Hamzaoglu
    Department of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Inflamm Bowel Dis 16:2109-16. 2010
    ..The aim of this study was to evaluate the short- and long-term safety experience of infliximab treatment in patients with Crohn's disease (CD) in clinical practice...
  20. ncbi Diverticular disease in the elderly
    R J Farrell
    Harvard Medical School, Boston, Massachusetts, USA
    Gastroenterol Clin North Am 30:475-96. 2001
    ..Endoscopic, radiologic, and surgical advances have increased the availability of more definitive therapies for patients with complicated diverticular disease and diverticular hemorrhage...
  21. ncbi Diagnostic and therapeutic ERCP: a large single centre's experience
    R J Farrell
    Department of Medicine and Gastroenterology, Trinity College Dublin, St James s Hospital, Ireland
    Ir J Med Sci 170:176-80. 2001
    ..Most large published series on endoscopic retrograde cholangiopancreatography (ERCP) are multicentre-based and consequently reflect varying experience...
  22. ncbi Guided versus blind liver biopsy for chronic hepatitis C: clinical benefits and costs
    R J Farrell
    Department of Hepatology, St James s Hospital, Trinity College Dublin, Ireland
    J Hepatol 30:580-7. 1999
    ....
  23. ncbi Recent advances in inflammatory bowel disease
    R J Farrell
    Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02115, USA
    Crit Rev Clin Lab Sci 38:33-108. 2001
    ..This article addresses our current understanding of the pathogenesis of IBD, including the latest developments in animal models and covers agents currently used in the treatment of IBD as well as emerging therapies...
  24. ncbi State-of-the-art ultrasonography is as accurate as helical computed tomography and computed tomographic angiography for detecting unresectable periampullary cancer
    M M Morrin
    Department of Radiology, Beth Israel Deacones Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Ultrasound Med 20:481-90. 2001
    ..If performed as the initial investigation and the region of the pancreatic head is clearly shown, and if vascular encasement or occlusion or distant metastasis is identified, further investigations are unnecessary...
  25. ncbi Smoking and immunomodulators do not influence the response or duration of response to infliximab in Crohn's disease
    David S Fefferman
    Divisions of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Inflamm Bowel Dis 10:346-51. 2004
    ..However, among patients with luminal or fistulous disease, neither smoking nor immunomodulators had any effect on response or duration of response...
  26. ncbi Clostridium difficile
    L Kyne
    Harvard Medical School, Gerontology Division, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Gastroenterol Clin North Am 30:753-77, ix-x. 2001
    ..Ultimately, active or passive immunization against C. difficile may be an effective means of controlling the growing problem of nosocomial C. difficile diarrhea and colitis...
  27. ncbi The combination of stricture dilation, endoscopic needle aspiration, and biliary brushings significantly improves diagnostic yield from malignant bile duct strictures
    R J Farrell
    Division of Gastroenterology and Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02115, USA
    Gastrointest Endosc 54:587-94. 2001
    ....
  28. ncbi Open-label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of a human monoclonal antibody to Clostridium difficile toxin A
    Claribel P Taylor
    Beth Israel Deaconess Medical Center, University of Massachusetts Medical School, Boston, Massachusetts, USA
    Vaccine 26:3404-9. 2008
    ..difficile toxin A are protective against symptomatic disease and recurrence. We examined the safety and pharmacokinetics (pk) of a novel neutralizing human monoclonal antibody against C. difficile toxin A (CDA1) in healthy adults...
  29. ncbi Development of chronic colitis is dependent on the cytokine MIF
    Y P de Jong
    Division of Immunology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Nat Immunol 2:1061-6. 2001
    ..Because we found increased plasma MIF concentrations in patients with Crohn's disease, these data suggested that MIF is a new target for intervention in Crohn's disease...
  30. ncbi Risk of early surgery for Crohn's disease: implications for early treatment strategies
    Bruce E Sands
    Gastrointestinal Unit and Center for the Study of IBD, Department of Medicine, Massachusetts General Hospital, 55 Fruit Street, GRJ 7, Boston, MA 02114, USA
    Am J Gastroenterol 98:2712-8. 2003
    ..These results suggest that improved risk stratification and potent therapies with rapid onset of action are needed to modify the natural history of Crohn's disease...
  31. ncbi The risk of lymphoma in the treatment of inflammatory bowel disease with immunosuppressive agents
    John H Kwon
    Center for Inflammatory Bowel Disease, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Dana 501, Boston, MA 02215, USA
    Crit Rev Oncol Hematol 56:169-78. 2005
    ....
  32. ncbi Celiac disease
    Daniel Leffler
    Am J Manag Care 9:825-31; quiz 832-3. 2003
    ....
  33. ncbi CT colonography in 546 patients with incomplete colonoscopy
    Laurian Copel
    Department of Radiology, Assaf Harofeh Medical Center, Sackler School of Medicine, Zerifin, Israel
    Radiology 244:471-8. 2007
    ..To retrospectively evaluate the positive predictive value (PPV) of computed tomographic (CT) colonography performed in patients who were referred for further examination after incomplete colonoscopy...
  34. ncbi Epidermal growth factor for ulcerative colitis
    Richard J Farrell
    N Engl J Med 349:395-7. 2003
  35. ncbi Recent advances in the understanding of celiac disease: therapeutic implications for the management of pediatric patients
    John H Kwon
    Division of Gastroenterology and Hepatology, Johns Hopkins University, Baltimore, Maryland, USA
    Paediatr Drugs 8:375-88. 2006
    ....
  36. ncbi Infliximab for induction and maintenance therapy for ulcerative colitis
    Alan C Moss
    Gastroenterology 131:1649-51; discussion 1651. 2006
  37. ncbi Adding fuel to the fire: GM-CSF for active Crohn's disease
    Alan C Moss
    Gastroenterology 129:2115-7. 2005
  38. ncbi Infant gluten and celiac disease: too early, too late, too much, too many questions
    Richard J Farrell
    JAMA 293:2410-2. 2005
  39. ncbi Equimolar doses of balsalazide and mesalamine: are we comparing apples and oranges?
    Richard J Farrell
    Am J Gastroenterol 97:1283-5. 2002